Can Nitazoxanide and/or other anti‐viral medications be a solution to long COVID? Case report with a brief literature review

KEY CLINICAL MESSAGE: Findings here imply lingering of virus, SARS‐CoV‐2, in the body for months. Thus, Nitazoxanide and/or other anti‐viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally. ABSTRACT: Long COVID or post‐acut...

Descripción completa

Detalles Bibliográficos
Autor principal: Stewart, Denise D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10654558/
https://www.ncbi.nlm.nih.gov/pubmed/38028066
http://dx.doi.org/10.1002/ccr3.8162
Descripción
Sumario:KEY CLINICAL MESSAGE: Findings here imply lingering of virus, SARS‐CoV‐2, in the body for months. Thus, Nitazoxanide and/or other anti‐viral medications might be potential options to combat long COVID. This could transform treatment for long COVID patients globally. ABSTRACT: Long COVID or post‐acute sequelae of COVID‐19 (PASC) continues to affect many people even after a relatively mild acute illness. Underlying causes of PASC are poorly understood. There is no particular treatment or management program developed yet. Thus, the possibility of well‐known, safe anti‐viral medications use against PASC is proposed here.

Ejemplares similares